Vyxeos (daunorubicin and cytarabine)

pCPA File Number: 21588

Negotiation Status:

Concluded with an LOI

Indication(s):

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) or newly diagnosed therapy-related acute myeloid leukaemia (t-AML) , in adults

Sponsor/Manufacturer:

Jazz Pharmaceuticals Canada Inc.

CDA-AMC Project Number:

PC0237-000

pCPA Engagement Letter Issued:

2022-01-13

Negotiation Process Concluded:

2022-04-27